CADL Insider Trading Activity and SEC Form 4 Filings
CADL insider trading summary
Over the past 12 months, insiders at Candel Therapeutics, Inc. (CADL) reported 5 sales worth $3.6M by 3 insiders and 1 open-market purchase worth $3.0M by 1 insider on SEC Form 4. Net insider selling was $551K.
Latest CADL insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 11, 2026 | Paul Peter Tak | Chief Executive Officer | Sell | $621K (59,379 @ $10.46) |
| Sep 10, 2026 | Paul Peter Tak | Chief Executive Officer | Sell | $2.5M (220,866 @ $11.50) |
| Aug 17, 2026 | Seshu Tyagarajan | Chief Technology Officer | Sell | $84K (7,000 @ $12.00) |
| Jun 29, 2026 | Seshu Tyagarajan | Chief Technology Officer | Sell | $70K (7,000 @ $10.02) |
| Jun 29, 2026 | Francesca Barone | Chief Scientific Officer | Sell | $236K (23,447 @ $10.06) |
| Feb 23, 2026 | Paul B Manning | Insider | Buy | $3.0M (550,458 @ $5.45) |
| Jul 28, 2025 | William Garrett Nichols | Chief Medical Officer | Sell | $7K (937 @ $6.98) |
| Jun 30, 2025 | William Garrett Nichols | Chief Medical Officer | Sell | $4K (781 @ $5.04) |
| Mar 19, 2025 | Paul Peter Tak | Chief Executive Officer | Sell | $4K (400 @ $9.00) |
| Mar 18, 2025 | Paul Peter Tak | Chief Executive Officer | Sell | $226K (25,772 @ $8.77) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.